Technology

Alteogen Inc. Wins All 14 U.S. Patent Trials and Lifts German Sales Ban

Germany Lifts Preliminary Injunction Banning Sales of Keytruda SC… Path to the German Market Reopens U.S. Patent Trial and Appeal Board Rejects All 14 of Halozyme’s Patents… Ruling Favors MSD Focus on the review of U.S. litigation proceedings on the 23rd, the U.K. trial on the 30th, and the Italian preliminary injunction hearing on the 2nd of next month

KIM SAE-MI
2026-11-20 10:55:03
[Edaily Reporter KIM SAE-MI ] "Keytruda SC," an immunotherapy drug developed by Alteogen Inc.(196170)using its subcutaneous (SC) formulation conversion technology, has secured favorable outcomes in patent disputes in both the U.S. and Germany. In the U.S., all 14 invalidation proceedings against a patent held by competitor Halozyme resulted in the patent being deemed invalid, while in Germany, a preliminary injunction that had blocked product sales was lifted.

Alteogen Inc. Headquarters and Research Institute (Photo: Alteogen Inc.)

According to the biotech industry on the 20th, Halozyme announced on the 19th (local time) that the Munich Higher Regional Court in Germany had revoked the preliminary injunction that had prohibited the distribution and sale of Keytruda SC in Germany.

Previously, in December of last year, the Munich Regional Court had granted the preliminary injunction banning sales after accepting the claim that Keytruda SC infringed on Halozime’s hyaluronidase-related patents. With this appellate court decision, U.S.-based Merck (MSD) has once again cleared the path to proceed with sales of Keytruda SC in Germany, Europe’s largest pharmaceutical market.

Halozime has objected to this decision and stated its intention to file a patent infringement lawsuit seeking a permanent sales ban in Germany. Mark Snyder, Chief Legal Officer (CLO) of Halozyme, stated, “We are disappointed that the preliminary injunction decision, which had halted the launch of Keytruda SC in Germany, has been overturned,” adding, “We disagree with this decision and will immediately file a patent infringement lawsuit against MSD in Germany.”

Halozime emphasized that the ruling issued last month by a Dutch court—which banned the manufacture and sale of Keytruda SC in eight European countries—remains in effect separately. Previously, the District Court of The Hague in the Netherlands ruled that Halozyme’s European Patent EP 2 797 622 (EP622) is valid and that Keytruda SC, which incorporates Alteogen Inc.’s ALT-B4, falls within the scope of protection of that patent.

Given that both the German preliminary injunction and the Dutch ruling involve disputes over the same European patent, EP622, attention is focused on the specific grounds for the German appellate court’s decision. However, since the revocation of the German preliminary injunction does not overturn the validity of the Dutch ruling, the patent dispute within Europe remains ongoing.

This German appellate court decision is also noteworthy because it came shortly after a series of patent trial rulings in the United States that favored MSD. On the 18th (local time), the Patent Trial and Appeal Board (PTAB) under the U.S. Patent and Trademark Office ruled that all claims subject to review in two post-grant review (PGR) proceedings filed by MSD against Halozyme lacked patentability.

The subject of these proceedings was two U.S. patents held by Halozyme relating to technology for modifying human hyaluronidase (PH20). The PTAB determined that the patents failed to meet the requirements for a detailed description of the invention and the enablement requirement under U.S. patent law.

The Patent Trial and Appeal Board determined that the scope of the modified enzymes for which Halozyme sought patent protection was not sufficiently supported by the specification and experimental data. This means the patents failed to meet the requirements for a detailed description of the invention and enablement under U.S. patent law.

Previously, MSD had filed a series of invalidation proceedings targeting Halozime’s “MDASE” patent portfolio beginning in November 2024. Including these two cases, final written decisions favorable to MSD have been issued in all 14 PGR cases where hearings have commenced. This effectively weakens Halozime’s basis for enforcing its patent rights against Keytruda SC in the United States.

This development is expected to have a positive impact on Alteogen Inc.’s financial performance. Keytruda SC incorporates “ALT-B4,” a core enzyme of the Hybrozyme platform that Alteogen Inc. licensed to MSD. Alteogen Inc. has signed an agreement entitling it to sales milestones of up to $1 billion (approximately 1.38 trillion won) based on Keytruda SC sales performance.

Alteogen Inc. had already announced in August that it had achieved its first sales milestone of $25 million (approximately 34.4 billion won at the time). According to MSD, global sales of Keytruda SC in the third quarter of this year reached $830 million (approximately 1.1454 trillion won), a 79.3% increase from the previous quarter’s $463 million (approximately 638.9 billion won). It is expected that once sales in Germany gain momentum, this will contribute to further revenue growth and the achievement of subsequent milestones.

The upcoming schedule for patent litigation is also drawing attention. On the 23rd, a hearing is scheduled at the U.S. District Court for the District of New Jersey to review proceedings related to the patent infringement lawsuit. On the 30th, a trial is set to begin in the U.K. to determine the validity and infringement of Halozyme’s separate European patent, EP347. On the 2nd of next month, the first hearing will be held in Italy on the preliminary injunction to halt sales that Halozyme filed against MSD’s local subsidiary and the contract manufacturer of Keytruda SC.

Economy

Corporation

IT·Science

Economy

Kim Jong-won: “Comprehensive Support for Blockchain Needed at the Financial Services Commission, Ministry of Science and ICT, and National Assembly Levels”

As the government’s draft of the Framework Act on Digital Assets—a key national policy initiative—is set to be submitted to the National Assembly shortly, industry representatives have called for comp…
2026-11-20 11:07:07

Corporation

HYUNDAI G.F. HOLDINGS, the holding company of the Hyundai Department Store Group, Added to the KOSPI 200 Index

HYUNDAIDEPARTMENTSTORECO.,LTD’s holding company, HYUNDAI G.F. HOLDINGS(005440), will be newly added to the KOSPI 200, South Korea’s leading stock index. HYUNDAI G.F. HOLDINGS CI. (Image courtesy o…
2026-11-20 10:27:24

IT·Science

Alteogen Inc. Wins All 14 U.S. Patent Trials and Lifts German Sales Ban

"Keytruda SC," an immunotherapy drug developed by Alteogen Inc.(196170)using its subcutaneous (SC) formulation conversion technology, has secured favorable outcomes in patent disputes in both the U.S.…
2026-11-20 10:55:03